An investigational aloe vera-based product for treating ulcerative colitis. While the product made it to Phase-3 trials, Carrington Laboratories, the sponsor, ended the trial as the treatment showed no therapeutic efficacy.
References in periodicals archive ?
Carrington currently holds approximately 120 patents, issued and pending, in 26 countries under which it manufactures its drug product Aliminase currently in Phase III clinical trials for the treatment of ulcerative colitis; Acemannan Immunostimulant, an injectable as an adjunct for the treatment of fibrosarcoma in dogs and cats; raw materials, such as Manapol Powder used in a variety of consumer and nutraceutical products; and acemannan hydrogel used in Carrington's proprietary wound care products.